DTP-HepB vaccine
| Combination of | |
|---|---|
| DTP vaccine | Vaccine |
| Hepatitis B vaccine | Vaccine |
| Names | |
| Trade names | Tritanrix-HepB |
| Clinical data | |
| WHO AWaRe | UnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽ |
| Routes of use | Intramuscular injection |
| External links | |
| AHFS/Drugs.com | UK Drug Information |
| Identifiers | |
| CAS Number |
|
| ATC code | |
DTP-HepB vaccine is a combination vaccine whose generic name is diphtheria and tetanus toxoids and whole-cell pertussis and hepatitis B (recombinant) vaccine (adsorbed) or DTP-Hep B. It protects against the infectious diseases diphtheria, tetanus, pertussis, and hepatitis B.[1]
A branded formulation, Tritanrix-HepB manufactured by GlaxoSmithKline, was granted marketing approval in the EU in 1996. Marketing approval lapsed in 2014.[2]
A review conducted in 2012 concluded that there was insufficient evidence to determine differences in safety and efficacy between DTP-HepB vaccine and Hib vaccine administered separately and pentavalent DTP-HepB-Hib vaccine.[3]
References
- ↑ World Health Organization; World Health Organization Department of Immunization, Vaccines and Biologicals (2004). Immunization in Practice: A Practical Guide for Health Staff. World Health Organization. p. 18. ISBN 9789241546515. Archived from the original on 11 January 2022. Retrieved 15 July 2018.
- ↑ "Tritanrix HepB". European Medicines Agency. Archived from the original on 15 July 2018. Retrieved 14 July 2018.
- ↑ Bar-On ES, Goldberg E, Hellmann S, Leibovici L (April 2012). "Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB)". The Cochrane Database of Systematic Reviews. 4 (4): CD005530. doi:10.1002/14651858.CD005530.pub3. PMID 22513932.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.